Sangamo and Pfizer Announce Phase 1/2 Interim Data for Investigational Hemophilia A Gene Therapy
Go back to Sangamo and Pfizer Announce Phase 1/2 Interim Data for Investigational Hemophilia A Gene Therapy| Pfizer Inc. (NYSE: PFE) | Delayed: 24.29 +0.62 (2.62%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $23.67 | 52 Week High | $37.39 | |||
| Open | $23.74 | 52 Week Low | $28.25 | |||
| Day High | $24.35 | P/E | 14.72 | |||
| Day Low | $23.74 | EPS | $1.65 | |||
| Volume | 59,948,644 | |||||
| Sangamo Biosciences, Inc. (NASDAQ: SGMO) | Delayed: 0.18 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.18 | 52 Week High | $9.91 | |||
| Open | $0.18 | 52 Week Low | $3.10 | |||
| Day High | $0.18 | P/E | N/A | |||
| Day Low | $0.18 | EPS | $-0.48 | |||
| Volume | 14,420,825 | |||||
